Histaminergic modulation in Tourette syndrome

Joanna H. Cox, Stefano Seri, Andrea E. Cavanna*

*Corresponding author for this work

Research output: Contribution to journalReview article

Abstract

Introduction: Tourette syndrome is a neurodevelopmental disorder characterized by multiple motor tics and at least one vocal/phonic tic. Clinical phenotypes show a wide variability, often incorporating behavioral symptoms. The exact pathophysiology of Tourette syndrome is unknown, however genetic vulnerability and alterations in dopaminergic neurotransmission have consistently been reported. Other biochemical pathways, including histaminergic neurotransmission, are likely to be involved but have received relatively little attention until recently. Areas covered: We conducted a systematic literature review focusing on the role of histaminergic neurotransmission and its pharmacological modulation in Tourette syndrome. We identified a number of relevant original studies published over the last five years, mainly focusing on genetic aspects. Expert opinion: There is converging evidence from recent studies supporting the hypothesis that histaminergic neurotransmission may play a role in the pathophysiology of Tourette syndrome. Most studies focused on the role of the histidine decarboxylase gene and the potential usefulness of histidine decarboxylase knockout mice as an experimental model for studying neurochemical function in Tourette syndrome. There have been no large scale studies assessing the use of histaminergic medications in the management of Tourette syndrome. This would be an important area for future research, with direct implications for the clinical management of selected phenotypes.

Original languageEnglish
Pages (from-to)205-213
Number of pages9
JournalExpert Opinion on Orphan Drugs
Volume4
Issue number2
Early online date5 Dec 2015
DOIs
Publication statusPublished - 5 Jan 2016

Fingerprint

Tourette Syndrome
Synaptic Transmission
Histidine Decarboxylase
Tics
Phenotype
Behavioral Symptoms
Expert Testimony
Knockout Mice
Theoretical Models
Pharmacology
Genes

Bibliographical note

This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Opinion on Orphan Drugs, on 5/1/16, available online: http://www.tandfonline.com/10.1517/21678707.2016.1128819

Keywords

  • animal models
  • histamine
  • tics
  • Tourette syndrome
  • treatment

Cite this

Cox, Joanna H. ; Seri, Stefano ; Cavanna, Andrea E. / Histaminergic modulation in Tourette syndrome. In: Expert Opinion on Orphan Drugs. 2016 ; Vol. 4, No. 2. pp. 205-213.
@article{643d1c77454946dbafa30536a446a5fa,
title = "Histaminergic modulation in Tourette syndrome",
abstract = "Introduction: Tourette syndrome is a neurodevelopmental disorder characterized by multiple motor tics and at least one vocal/phonic tic. Clinical phenotypes show a wide variability, often incorporating behavioral symptoms. The exact pathophysiology of Tourette syndrome is unknown, however genetic vulnerability and alterations in dopaminergic neurotransmission have consistently been reported. Other biochemical pathways, including histaminergic neurotransmission, are likely to be involved but have received relatively little attention until recently. Areas covered: We conducted a systematic literature review focusing on the role of histaminergic neurotransmission and its pharmacological modulation in Tourette syndrome. We identified a number of relevant original studies published over the last five years, mainly focusing on genetic aspects. Expert opinion: There is converging evidence from recent studies supporting the hypothesis that histaminergic neurotransmission may play a role in the pathophysiology of Tourette syndrome. Most studies focused on the role of the histidine decarboxylase gene and the potential usefulness of histidine decarboxylase knockout mice as an experimental model for studying neurochemical function in Tourette syndrome. There have been no large scale studies assessing the use of histaminergic medications in the management of Tourette syndrome. This would be an important area for future research, with direct implications for the clinical management of selected phenotypes.",
keywords = "animal models, histamine, tics, Tourette syndrome, treatment",
author = "Cox, {Joanna H.} and Stefano Seri and Cavanna, {Andrea E.}",
note = "This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Opinion on Orphan Drugs, on 5/1/16, available online: http://www.tandfonline.com/10.1517/21678707.2016.1128819",
year = "2016",
month = "1",
day = "5",
doi = "10.1517/21678707.2016.1128819",
language = "English",
volume = "4",
pages = "205--213",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "2",

}

Histaminergic modulation in Tourette syndrome. / Cox, Joanna H.; Seri, Stefano; Cavanna, Andrea E.

In: Expert Opinion on Orphan Drugs, Vol. 4, No. 2, 05.01.2016, p. 205-213.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Histaminergic modulation in Tourette syndrome

AU - Cox, Joanna H.

AU - Seri, Stefano

AU - Cavanna, Andrea E.

N1 - This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Opinion on Orphan Drugs, on 5/1/16, available online: http://www.tandfonline.com/10.1517/21678707.2016.1128819

PY - 2016/1/5

Y1 - 2016/1/5

N2 - Introduction: Tourette syndrome is a neurodevelopmental disorder characterized by multiple motor tics and at least one vocal/phonic tic. Clinical phenotypes show a wide variability, often incorporating behavioral symptoms. The exact pathophysiology of Tourette syndrome is unknown, however genetic vulnerability and alterations in dopaminergic neurotransmission have consistently been reported. Other biochemical pathways, including histaminergic neurotransmission, are likely to be involved but have received relatively little attention until recently. Areas covered: We conducted a systematic literature review focusing on the role of histaminergic neurotransmission and its pharmacological modulation in Tourette syndrome. We identified a number of relevant original studies published over the last five years, mainly focusing on genetic aspects. Expert opinion: There is converging evidence from recent studies supporting the hypothesis that histaminergic neurotransmission may play a role in the pathophysiology of Tourette syndrome. Most studies focused on the role of the histidine decarboxylase gene and the potential usefulness of histidine decarboxylase knockout mice as an experimental model for studying neurochemical function in Tourette syndrome. There have been no large scale studies assessing the use of histaminergic medications in the management of Tourette syndrome. This would be an important area for future research, with direct implications for the clinical management of selected phenotypes.

AB - Introduction: Tourette syndrome is a neurodevelopmental disorder characterized by multiple motor tics and at least one vocal/phonic tic. Clinical phenotypes show a wide variability, often incorporating behavioral symptoms. The exact pathophysiology of Tourette syndrome is unknown, however genetic vulnerability and alterations in dopaminergic neurotransmission have consistently been reported. Other biochemical pathways, including histaminergic neurotransmission, are likely to be involved but have received relatively little attention until recently. Areas covered: We conducted a systematic literature review focusing on the role of histaminergic neurotransmission and its pharmacological modulation in Tourette syndrome. We identified a number of relevant original studies published over the last five years, mainly focusing on genetic aspects. Expert opinion: There is converging evidence from recent studies supporting the hypothesis that histaminergic neurotransmission may play a role in the pathophysiology of Tourette syndrome. Most studies focused on the role of the histidine decarboxylase gene and the potential usefulness of histidine decarboxylase knockout mice as an experimental model for studying neurochemical function in Tourette syndrome. There have been no large scale studies assessing the use of histaminergic medications in the management of Tourette syndrome. This would be an important area for future research, with direct implications for the clinical management of selected phenotypes.

KW - animal models

KW - histamine

KW - tics

KW - Tourette syndrome

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=84958112778&partnerID=8YFLogxK

U2 - 10.1517/21678707.2016.1128819

DO - 10.1517/21678707.2016.1128819

M3 - Review article

AN - SCOPUS:84958112778

VL - 4

SP - 205

EP - 213

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 2

ER -